MedTrace Logo

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

NCT03253068 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-05-19

No results posted yet for this study

Summary

To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

Pembrolizumab plus amurubicin

Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Hiroaki Akamatsu, M.D. · Third Department of Internal Medicine, Wakayama Medical University

  • Nobuyuki Katakami, M.D., Ph.D. · Division of Integrated Oncology, Institute of Biomedical Research and Innovation

  • Kazuhiko Nakagawa, M.D., Ph.D. · Department of Medical Oncology, Kinki University, Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-12-28
Completion
2020-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253068 on ClinicalTrials.gov